GATINEAU, Quebec - s4story -- Eurostars, a European funding program for innovative R&D projects, announced today that Macadamian has been recognized and ranked as the top project for the 2019 Eurostars Eureka innovation project funding for X-AID, an AI-driven radiology clinical decision support software tool. In addition to the award, Macadamian received a $495,000 grant from Eurostars and the National Research Council of Canada in April of this year. The subsidy is for a three-year period to develop and commercialize the solution.

Eurostars is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries which include Canada through Horizon 2020. To date, Eurostars has funded more than 7,000 innovation projects worldwide with a total value of approximately $61 billion Canadian.

More on S For Story

• Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
• Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
• From Barrio to Transgender Pioneer: Chapter 12 of A Letter to Pawtone
• $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
• West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care

"We are thrilled to receive the grant and to be working on the development of a leading-edge diagnostic tool and we look forward to working with forward-thinking providers to pilot it," said Frederic Boulanger, CEO Macadamian. Boulanger added, "Our X-AID proposal was ranked an impressive 1st place submission beating out 283 eligible applicants. This is a very strong endorsement of our deep and wide experience in healthcare technology and analytics. This is something the whole team at Macadamian is extremely proud of."

According to Timon LeDain, Director of Emerging Technologies, Macadamian, "X-AID is focused on addressing the global challenge associated with the growing shortage of highly specialized radiologists in addition to the increasing demand to deliver faster and more accurate diagnoses of routine X-ray images of bones and joints. The solution is unique in that it uses fully automated machine learning (ML) algorithms and deep convolutional neural networks (CNNs) to deliver highly accurate diagnoses."

More on S For Story

• The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
• Kimberley Strunk's Inspiring New Book, "Jumping Boundaries,"
• Casting Pro Darya Balyura Named Judge for 2025 Meals 4 Monologues Virtual Showcase
• "Even the Crumbs Are Enough" — New Book Ignites Faith in a Time of Silence, Doubt, and Spiritual Exhaustion
• Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild

X-AID is being developed on Macadamian HealthConnect™ a digital health Platform-as-a-Service that Macadamian's healthcare experts use as the underlying architecture to accelerate the development of data-driven medical device and digital therapeutic software applications for our clients. Radiobotics, is providing the underlying AI and ML algorithms. Clinical evaluation of X-AID will be undertaken by the Bispebjerg Hospital and begin in October 2019.

###

About Macadamian
We design and develop digital and connected experiences to improve healthcare. Macadamian is a full-service software design and development consulting firm that provides a complete range of product strategy, user experience design and research, and software engineering services.